BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 30/07/2008

FDA Releases Draft Guidance for Industry on Reducing Parvovirus B19 Risk in Plasma-Derived Products

The FDA has made available a draft document outlining recommendations for manufacturers of plasma-derived products to perform nucleic acid testing to reduce the risk of parvovirus B19 transmission, with the goal of preventing the use of contaminated plasma units.

Source: Federal Register — Food and Drug AdministrationOpen original release →